Back to School: How biopharma can reboot drug development. Access exclusive analysis here
CELG will acquire PHRM for $72 per share, consisting of $25 in cash and the rest in CELG stock, for a total of $2.9 billion. The price is a 46%
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury